Abstract: FR-PO493
Patient-Reported Outcome Measures (PROMs) and Expanded Hemodialysis (HDx) with Medium Cut-Off Dialyzers in a Large Cohort of Patients in Colombia: The COREXH Study
Session Information
- Hemodialysis and Frequent Dialysis - IV
November 08, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Dialysis
- 701 Dialysis: Hemodialysis and Frequent Dialysis
Authors
- Sanabria, Mauricio, RTS, Bogotá, Colombia
- Rivera, Angela S., Baxter Healthcare Corporation, Deerfield, Illinois, United States
- Bernardo, Angelito A., Baxter Healthcare Corporation, Deerfield, Illinois, United States
- Nilsson, Lars-Goran, Baxter International Inc., Lund, Sweden
- Vesga, Jasmin, RTS, Bogotá, Colombia
- Bunch, Alfonso, RTS, Bogotá, Colombia
- Sanchez, Ricardo, Universidad Nacional de Colombia, Bogotá, Colombia
Background
Increasing importance and focus have been directed towards quality of life measures (QoL) and patient experience in end stage kidney patients on hemodialysis (HD). A new therapy, expanded hemodialysis(HDx) with Theranova membane improved clearance of middle molecular uremic toxins but to date its effects of QoL are lacking
Methods
Historical cohort, multicenter study in prevalent patients older than 18 years under the HDx therapy with MCO membrane that complete the twelve months of follow up in the COREXH Registry, in Renal Therapy Services (RTS) Colombia network. PROMs were assessed by KDQOL-36, Dialysis Symptoms Index (DSI), and diagnostic criteria for Restless Legs Syndrome (RLS) tools. The ANOVA and Cochran’s Q test was used.
Results
Out of 992, the 619 men (62.4%) with mean age 60.4±15.7 years. For KDQoL 36 domains, symptoms, burden and effects of kidney disease and mental component, significant increase in score at 6 and 12 mos was noted ( Table1 ). ANOVA for DSI shows statistically significant differences in mean severity scores over the follow-up with improvement from 30.7, 29.9 and 28.5 at baseline, six months and one year respectively, (F (2, 1450) = 6.92, p = 0.0087)). The proportion of patients with RLS scores improved from 22.11% at baseline, to 12.47% at 6 m and 9.98 at 12 m (Cochran’s Q, 2 df) = 145.42, p < 0.0001.
Conclusion
In this large multicenter study, HDx with Theranova resulted in improved patients’ related outcomes.
Patient Reported Outcome Measures
| KDQoL – 36 domains | Baseline (N=971) Mean (SD) | At Six Months (N=808) Mean (SD) | At Twelve Months (N=642) Mean (SD) | p-Value |
| Sympton/Problem Domain | 78.6 (15.8) | 81.0 (15.4) | 81.5 (14.9) | < 0.0001 * |
| Effect of Kidney Disease | 69.7 (22.03) | 72.8 (22) | 75.1 (21) | < 0.0001* |
| Burden of Kidney Disease | 46.2 (27.5) | 48.9 (29.9) | 50.2 (32.3) | < 0.0012* |
| SF-12 Physical | 41.1 (11.1) | 41.0 (11.2) | 41.7 (10.5) | 0.27* |
| SF-Mental | 51.1 (11.6) | 51.9 (11.3) | 52.3 (11.1) | < 0.0016* |
| DSI | 30.7 (22.3) | 29.9 (32) | 28.5 (21.7) | 0.0087 * |
| RLS | ||||
| % of patients with RLS | 22.1 | 12.47 | 9.98 | < 0.0001** |
* Anova test ** Cochran’s Q test KDQOL-36: Kidney Disease Quality of Life-36 DSI: Dialysis Symptoms Index RLS: Diagnostic criteria for Restless Legs Syndrome
Funding
- Commercial Support – Baxter Healthcare Corporation